Plasma fractionation is a method used for segregating plasma into its different components. Proteins present in plasma are mainly used for therapeutic purposes in the treatment of various diseases. Factors primarily responsible for the growth of the plasma fractionation market are increased prevalence of rare diseases, surge in geriatric population, and growing use of immunoglobulins in different therapeutic domains.
In the plasma fractionation market, laboratories, hospitals, and academic institutes are the prime end users. In 2018, hospitals are estimated to be the largest end-user category in the market, characterized by the availability of large and sophisticated devices; and presence of skilled professionals. Presence of different operating rooms and diagnosis facility in hospitals are predicted to boost the growth of the market for this category. This is due to the fact that a large number of equipment for testing and analysis are required in the hospitals.
Request for sample copy of this report at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample
The major growth driver for the plasma fractionation industry is the rising number of patients suffering from rare autoimmune diseases. According to the facts stated by National Institute of Environmental Health Sciences (NIEHS) in 2018, rare autoimmune diseases affect more than 23.5 million people in the U.S. Moreover, NIEHS also supports various clinical research institutes on how immunity and environmental factors work together to compromise the body’s ability to defend itself, and develop into autoimmune diseases. For instance, National Toxicology Program (NTP) by NIEHS is involved in researching on the link between genetic predisposition and environmental triggers.
Rising prevalence rate of immunodeficiency diseases also serves as a key driving factor for the plasma fractionation market growth. PIDD, multiple sclerosis, and immune thrombocytopenia purpura (ITP) are some of the examples of rare immune diseases that have high prevalence rate, globally. According to the reports by Immune Deficiency Foundation (IDF), in 2018, there were approximately 250,000 people diagnosed with PIDD.
Some of the key players operating in the plasma fractionation industry are CSL Behring, Japan Blood Products Organization, Green Cross Corp., Bio Product Laboratory Ltd., Octapharma AG, Kedrion S.p.A., and Grifols International S.A.
This post was originally published on Raleigh Recorder